NervGen Pharma Corp. NGEN
NervGen Pharma Corp. (Nasdaq: NGEN) is a CNS/neurology/psychiatry drug developer. Its lead program, NVG-291, is in Phase 2 for Spinal cord injury (chronic and subacute tetraplegia).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NVG-291 (CONNECT SCI Phase 1b/2a, chronic and subacute cohorts) | Spinal cord injury | protein/peptide | Phase 2 |
| NVG-300 | Neurotraumatic/neurologic conditions (SCI, stroke models) | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 16, 2026clinical hold NVG-291 for SCI is currently subject to a partial clinical hold by the FDA.
NVG-291 for SCI is currently subject to a partial clinical hold by the FDA, and we may be unable to have the hold removed
Filing - Aug 13, 2026positive Independent blinded biomechanical gait analyses from CONNECT SCI showed statistically significant improvement in gait quality (coordination, mechanical effort, postural stability).
Announced positive results from independent, blinded biomechanical gait analyses from CONNECT SCI, demonstrating statistically significant improvement in gait quality across established hallmarks of SCI-specific recovery: coordination, mechanical effort, and postural stability.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.